# Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

> **NCT07646145** · PHASE2 · RECRUITING · sponsor: **Shanxi Province Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non-Muscle-Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** Disitamab Vedotin
- **DRUG:** Mitomycin C (MMC)

## Key facts

- **NCT ID:** NCT07646145
- **Lead sponsor:** Shanxi Province Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646145, "Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07646145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*